The GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTUse code WELCOME10 for 10% off your orderFREE FEDEX 2-DAY shipping on orders over $250!Military · Veterans · First Responders: Verify & Save →Free gift on orders $300+ · choose GLP-3 RT 5MG, GHK-Cu 100MG, NAD+ 500MG or MOTs-C 10MGUse code WELCOME10 for 10% off your orderFREE FEDEX 2-DAY shipping on orders over $250!Military · Veterans · First Responders: Verify & Save →
Research Guide

MK-677 (Ibutamoren)
Research Guide

A Research Use Only reference to MK-677: identity data, what published studies examined, handling and storage for laboratories.

Research reference · Updated October 11, 2026 · How we check our guides

What is MK-677?

MK-677, also written MK677 or MK 677, is ibutamoren, an orally active, non-peptide growth hormone secretagogue developed by Merck as MK-0677 and L-163,191. Merck reported in 1995 that it raised growth hormone in dogs given it by mouth (Patchett et al., 1995).

It is an agonist of the growth hormone secretagogue receptor (GHS-R1a), whose natural ligand, the stomach hormone ghrelin, was identified in 1999 (Kojima et al., 1999). Human trials followed through the 1990s and 2000s, but it did not become an approved drug. Disguised Alpha supplies it in 10MG capsules, 60 per bottle, for laboratory research use only. Nothing on this page is guidance for use in people.

MK-677 reference data

PropertyValue
NameMK-677 (ibutamoren)
Also calledMK677, MK 677, MK-0677, L-163,191; ibutamoren mesylate for the salt form
StructureN-methanesulfonyl spiro(indoline-3,4'-piperidine) core joined by amide bonds to O-benzyl-D-serine and 2-aminoisobutyric acid; not a peptide chain
Compound classNon-peptide growth hormone secretagogue; ghrelin receptor (GHS-R1a) agonist
Molecular formulaC₂₇H₃₆N₄O₅S (free base)
Molecular weight528.7 g/mol (free base)
PubChem CID178024
Mesylate salt, for referenceC₂₈H₄₀N₄O₈S₂, 624.8 g/mol (PubChem CID 6450830)
FormCapsules, 10MG per capsule, 60 capsules per bottle (600MG per bottle)
TestingThird-party tested, with the certificate for each lot published on the product page and in the COA portal

Formula, molecular weight, capsule format and storage are from the MK-677 product page. That formula and weight match the ibutamoren free base in PubChem (CID 178024), the source of the aliases and structure. A PubChem search for MK-677 returns the mesylate salt (CID 6450830), the form Merck's trial papers name (Sevigny et al., 2008). Check your lot's certificate for the form the capsules hold before molar calculations.

See it beside the other compounds on this site in the peptide molecular weight reference table.

What the research covers

Published work on MK-677 falls into six areas. Each summary below states the model used. Its many human trials appear as research history, with findings as the papers reported them.

Discovery as an oral, non-peptide secretagogue

Earlier growth hormone secretagogues, such as GHRP-6, were peptides. Merck's L-163,191 (MK-0677) released growth hormone from cultured rat pituitary cells with an EC50 of 1.3 nM, acted like GHRP-6 rather than growth hormone-releasing hormone (GHRH), and in dogs raised growth hormone without significant changes in aldosterone, LH, thyroxine or prolactin (Patchett et al., 1995). In beagles, oral MK-0677 raised peak growth hormone up to 15.8 fold, kept it elevated for up to 6 hours and raised IGF-I by about 30 percent (Jacks et al., 1996). Models: rat pituitary cells and dogs.

The ghrelin receptor

Merck scientists then cloned the target, a G protein-coupled receptor in pig and human pituitary and hypothalamus now called GHS-R1a, and proposed that the secretagogues mimic an undiscovered hormone (Howard et al., 1996). That hormone, ghrelin, was purified from rat stomach in 1999 as a 28-amino-acid peptide carrying an octanoyl group essential for activity (Kojima et al., 1999). Cryo-electron microscopy structures later showed how ghrelin and ibutamoren each sit in the human receptor's binding pocket (Liu et al., 2021). Models: cloned receptors, rat stomach extracts and purified receptor complexes.

Short-term human studies

In a placebo-controlled trial in 32 healthy adults aged 64 to 81, daily oral MK-677 raised mean 24-hour growth hormone by 97 percent after 2 weeks at the highest of three amounts tested; by 4 weeks IGF-I had reached the young-adult range and fasting glucose had risen (Chapman et al., 1996).

In eight volunteers on a calorie-restricted diet, mean daily nitrogen balance in a crossover week was 0.31 g with MK-677 against minus 1.48 g with placebo (Murphy et al., 1998). In 24 obese men over 8 weeks, fat-free mass rose, body fat did not change and glucose tolerance worsened (Svensson et al., 1998). Models: randomized human studies.

Year-long trials

The longest trial randomized 65 healthy adults aged 60 to 81 to MK-677 or placebo for two years. Growth hormone and IGF-I reached young-adult levels and fat-free mass rose 1.1 kg against a 0.5 kg fall on placebo, but visceral fat, total fat, strength and function did not differ. Fasting glucose rose, insulin sensitivity fell, and increased appetite, mild leg swelling and muscle pain were the most frequent side effects (Nass et al., 2008).

In 563 people with mild to moderate Alzheimer's disease, 12 months of MK-677 raised IGF-1 about 73 percent but did not slow progression (Sevigny et al., 2008). A phase IIb trial in 123 older adults after hip fracture was stopped early after a congestive heart failure signal in a few patients, and most functional measures did not differ from placebo (Adunsky et al., 2011). Models: randomized, placebo-controlled trials.

Animal models

In rats, oral MK-677 first raised peak growth hormone 1.8 fold. After six weeks, body growth and IGF-I had not increased, the response was gone and hypothalamic somatostatin expression had risen, which the authors linked to desensitization (Lee et al., 2018). In 5xFAD mice, a model of Alzheimer's-type amyloid pathology, MK-0677 increased hippocampal neurogenesis but did little to prevent amyloid deposition, synaptic loss or cognitive deficits, and mortality rose in mice that received 3 mg/kg (Tian et al., 2019). Models: rats and transgenic mice (animal data only).

Children with growth hormone deficiency

In 18 prepubertal children with idiopathic growth hormone deficiency, 7 to 8 days of oral ibutamoren mesylate raised peak growth hormone, IGF-I and IGFBP-3 in some children, with no change in prolactin, glucose, thyroid hormones or cortisol (Codner et al., 2001). Lumos Pharma later studied the compound as LUM-201. In 68 children in a growth hormone deficiency trial, the response to one oral challenge exceeded that to standard stimulation tests, with medians of 15.0 against 5.5 ng/mL; both authors consulted for the developer (Bright and Thorner, 2022). Models: pediatric clinical studies.

Key studies

  1. Patchett AA, et al. "Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue." Proc Natl Acad Sci U S A. 1995. PMID 7624358. DOI 10.1073/pnas.92.15.7001. Rat pituitary cells and dogs: discovery and selectivity.
  2. Murphy MG, et al. "MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism." J Clin Endocrinol Metab. 1998. PMID 9467534. DOI 10.1210/jcem.83.2.4551. Crossover study in eight calorie-restricted volunteers: nitrogen balance and IGF-I.
  3. Nass R, et al. "Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial." Ann Intern Med. 2008. PMID 18981485. DOI 10.7326/0003-4819-149-9-200811040-00003. 65 adults aged 60 to 81 over two years: body composition, insulin sensitivity and function.
  4. Sevigny JJ, et al. "Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial." Neurology. 2008. PMID 19015485. DOI 10.1212/01.wnl.0000335163.88054.e7. 563 people with Alzheimer's disease over 12 months: no effect on progression.
  5. Liu H, et al. "Structural basis of human ghrelin receptor signaling by ghrelin and the synthetic agonist ibutamoren." Nat Commun. 2021. PMID 34737341. DOI 10.1038/s41467-021-26735-5. Cryo-EM structures of the receptor with ghrelin or ibutamoren.

Handling and storage of MK-677 capsules

General laboratory practice for this material:

  • Store the sealed capsules at 15 to 25°C in the original container, away from moisture and direct light (storage guidance on the product page).
  • Capsules ship in a sealed bottle or a resealable pouch, depending on the batch; close it fully after each opening.
  • Record the lot number. The certificate reports measured content per capsule, which can differ from the 10MG label, so use the measured value.
  • Base molar calculations on the form named on the certificate: the free base is 528.7 g/mol and the mesylate salt is 624.8 g/mol.
  • For identity checks, compare analytical data with C₂₇H₃₆N₄O₅S; the lot MK01 certificate, for example, reports identity by LC-MS and purity by HPLC-UV.

Frequently asked questions

What is MK-677?

MK-677 (MK677, MK 677) is ibutamoren, a small-molecule ghrelin receptor agonist that Merck developed as an orally active growth hormone secretagogue (Patchett et al., 1995). In human trials it raised growth hormone and IGF-1 (Nass et al., 2008).

Is MK-677 a peptide?

No. MK-677 is a spiropiperidine small molecule built on a spiro(indoline-3,4'-piperidine) core. Papers describe it as a non-peptide growth hormone secretagogue (Codner et al., 2001) and a non-peptide ghrelin receptor agonist (Liu et al., 2021). The "MK-677 peptide" label reflects its role: it was designed to mimic growth hormone-releasing peptides (Chapman et al., 1996), it acts at the receptor for the peptide hormone ghrelin, and it is often sold beside peptides.

How does MK-677 differ from ipamorelin and GHRH analogs?

MK-677 and ipamorelin both act at the ghrelin receptor, but ipamorelin is a five-residue peptide and MK-677 is a non-peptide small molecule. GHRH analogs such as tesamorelin and CJC-1295 act at a different receptor, the GHRH receptor, and Merck showed that MK-0677 acted differently from GHRH (Patchett et al., 1995).

Has MK-677 been tested in people?

Yes, as research history. In randomized trials, several run by Merck, MK-677 raised IGF-1, but the Alzheimer's trial found no effect on progression (Sevigny et al., 2008), and the hip fracture trial stopped early after a congestive heart failure signal (Adunsky et al., 2011). A 2025 case report described raised liver enzymes, which later normalized, in a man who had used MK-677 for two months (Cobani et al., 2025). MK-677 is not an approved drug.

Is MK-677 on the WADA prohibited list?

Yes. The World Anti-Doping Agency names ibutamoren (MK-677) as a growth hormone secretagogue in section S2.2.4 of its Prohibited List, and section S2 substances are prohibited at all times.

Where can researchers buy MK-677?

Disguised Alpha sells MK-677 for laboratory research as 10MG capsules, 60 per bottle, third-party tested with the certificate for each lot published on the product page: MK-677 (Ibutamoren).

Related compounds and guides

This product is for research use only. It has not been evaluated for safety or effectiveness in humans. Not for human consumption. All products are intended for laboratory research purposes only.

Certificates of analysis

Each tested batch of MK677 (Ibutamoren) has its own certificate page with the full lab results.

25% offGLPs15% off automaticallyUse code GLP or any code for 25% off0days00hrs00min00secShop the sale  →Shop